Screener
ImmunityBio, Inc. IBRX Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Selling, general and administrative | 44,461 | 31,977 |
| Selling, general and administrative – related parties | 1,309 | 677 |
| Total operating costs and expenses | 113,997 | 80,946 |
| Loss from operations | (69,791) | (64,429) |
| Other income (expense), net | ||
| Interest and investment income, net | 2,314 | 887 |
| Change in fair value of warrant liabilities | (295,413) | (448) |
| Change in fair value of related-party convertible note | (236,625) | (42,582) |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s operating income?
- ImmunityBio, Inc. (IBRX) reported operating income of -$69.79M in Q1 2026.
- How has ImmunityBio, Inc.'s operating income changed year-over-year?
- ImmunityBio, Inc.'s operating income decreased by 8.3% year-over-year, from -$64.43M to -$69.79M.
- What is the long-term trend for ImmunityBio, Inc.'s operating income?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s operating income has grown at a -6.2% compound annual growth rate (CAGR), from -$330.28M to -$256.03M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about ImmunityBio, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude